$PHIN

PHIN Maintained by UBS -- Price Target Lowered to $68.00

UBS maintained a Neutral rating on Phinia (PHIN) but lowered its price target from $80.00 to $68.00, citing cautious near-term outlook. GuruFocus values PHIN at $58.97, slightly undervalued. Insider selling totaled $3.7 million over three months. PHIN has a GF Score of 81/100, showing strong profitability and momentum but challenges in growth and financial strength.

Original reporting
Published Oct 7, 2026, 9:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 10:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$PHIN
Bearish
medium confidence
Mentioned
$PHIN
Relevance
7/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$PHINBearishMed
01

Why it matters

The downgrade in price target may prompt short‑term selling pressure, but the neutral rating leaves room for upside if earnings beat expectations.

02

Market read

Analyst target cut is a fresh catalyst for PHIN, offering a potential trade signal for short‑term investors.

03

What to watch

Insider selling and mixed guru activity may already price in downside risk.

Relevance 7/10Novelty 7/10Timing: same day

Background

UBS released an analyst rating update for PHIN, adjusting its price target amid mixed insider and guru activity.

Company-level read

Ticker impact

$PHINBearishMedium confidence
Context

UBS maintained a Neutral rating on PHIN and cut its price target from $80 to $68, indicating a more cautious outlook.

Expected impact

likely downward pressure as investors price in the lower target

Evidence & confidence

A $12 price‑target cut for a $2.1B market‑cap signals reduced upside and may trigger sell‑side activity.

Market effects

May dampen sentiment in the Consumer Cyclical – Vehicles & Parts sub‑sector.

Primarily affects U.S. investors with exposure to PHIN.

Limited to PHIN and its peers; no broader macro impact.

Counterpoint

The price‑target cut could be over‑reactive if PHIN's underlying fundamentals remain strong.

Key entities

  • Phinia Inc.

    Consumer cyclical vehicle components manufacturer (ticker PHIN).

  • UBS

    Provided the rating and price‑target revision.

Related articles

$PHINMed

Phinia (PHIN) Q2 2026 Earnings Call Transcript

Phinia (PHIN) reported Q2 2026 results on an earnings call. Net sales were $940 million, up 5.6% year over year, with adjusted EBITDA of $130 million (13.8% margin) and adjusted EPS $1.53 (up 20.5%). Cash was $370 million, liquidity $820 million, net leverage 1.3x. The company returned $53 million via buybacks and dividends.

$PHINMedAI 8/10

PHINIA Inc. Q2 2026 Earnings Call Summary

PHINIA’s Q2 2026 call cited 5.6% revenue growth driven by Fuel Systems and Aftermarket demand. Adjusted EPS rose 20.5%. Full-year 2026 revenue guidance was refined to $3.57B-$3.67B and adjusted EBITDA to $485M-$515M. Free cash flow was raised to $210M-$250M. The stoba Group acquisition is expected to close in Q4 2026.

$PHINHighAI 9/10

Phinia (PHIN) Q2 2026 Earnings Call Transcript

Thursday, July 30, 2026, at 8:30 a.m. ET CALL PARTICIPANTS Vice President and Treasurer - Gordon Muir Chief Executive Officer - Brady Ericson Chief Financial Officer - Chris Gropp TAKEAWAYS Net Sales -- $940 million, growing 5.6% year over year driven by volume growth in both the Fuel Systems and Aftermarket segments. Fuel Systems Sales -- $584 million, a 5% increase year over year reflecting steady demand in key end markets.

$PHINMed

PHINIA REPORTS SECOND QUARTER 2026 RESULTS

PHINIA INC. (PHIN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PHINIA REPORTS SECOND QUARTER 2026 RESULTS Auburn Hills, Michigan, July 30, 2026 – PHINIA Inc. (NYSE: PHIN), a diversified, industrial supplier and global leader in the development of fuel systems, electrical systems, and aftermarket solutions, today reported results

$GMABMedAI 8/10

Genmab reports phase 2 trial data for colorectal cancer drug

Genmab (NASDAQ:GMAB) reported Phase 2 trial data for petosemtamab in metastatic colorectal cancer, showing 75% and 67% response rates in first- and second-line patients, respectively. The trial involved 79 patients and was presented at the European Society for Medical Oncology Congress 2026. Genmab is conducting four Phase 3 trials and will host an investor update.